Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Biopharmaceutical CMO and CRO Market by Product (Biologics, Biosimilars), by Source (Mammalian, Non-Mammalian) and by Service Type (Contract Manufacturing, Contract Research): Global Opportunity Analysis and Industry Forecast, 2023-2032

A13188

Pages: NA

Charts: NA

Tables: NA

Biopharmaceutical CMO and CRO Market Overview 2030

A contract manufacturing organization (CMO) is an organization that serves other companies in the pharmaceutical industry on a contract basis to provide comprehensive services for new drug developments through drug manufacturing. This helps the major pharmaceutical companies to outsource those aspects of the business which allow major companies to focus on drug discovery and drug marketing.

A contract research organization (CRO) is an organization that provides support to the pharmaceutical, biotechnological, and medical device industries in the form of research services which are on contract basis. Contract research organization provide services such as biopharmaceutical development, biological assay development, commercialization, preclinical research, clinical trials, and pharmacovigilance.

COVID-19 Impact Analysis             

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the biopharmaceutical CMO and CRO market.

Top Impacting Factors

  • Increase in demand for novel therapeutics, rise in integration of single-use systems in production facilities, surge in incidence of chronic diseases, increase in production rate of drugs, and rise in demand for biosimilars products in market is expected to drive the growth of the market.
  • In addition, increase in adoption of advance healthcare information technology sector, surge in usage of outsourcing activities, rise in expenditure to build modern infrastructures, increase in R & D activities to improve technology in biopharmaceutical sector, and surge in drug discovery & drug development procedures are some factors that fuel the growth of the biopharmaceutical CMO and CRO market.
  • However, high cost of biopharmaceutical CMO & CRO services and data security threats restrain the growth of the biopharmaceutical CMO and CRO market.
  • Contrarily, rise in demand for contract research and contract manufacturing organization is expected to offer lucrative opportunities for the expansion of the market.

Market Trends

Business Expansion to Flourish the Market

In 2020, J-Star Research Inc., announced launch of new website which will help company to lead in contract research organization focused on small molecule process research and crystallization R & D.

In 2019, ANI Pharmaceuticals announced merger with WellSpring Pharma expansion of contract manufacturing organization. This expansion will help ANI pharmaceuticals to speed up drug development and drug manufacturing process

Key Benefits of the Report

  • This study presents the analytical depiction of biopharmaceutical CMO and CRO market industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the biopharmaceutical CMO and CRO market share.
  • The current market is quantitatively analyzed to highlight the biopharmaceutical CMO and CRO market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the Biopharmaceutical CMO and CRO Market Report    

  • Which are the leading players active in the biopharmaceutical CMO and CRO market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What is "biopharmaceutical CMO and CRO"?
  • What is "biopharmaceutical CMO and CRO" market prediction in the future?
  • Who are the leading global players in the "biopharmaceutical CMO and CRO" market?
  • What are the current trends and predicted trends?
  • What are the key benefits of the "biopharmaceutical CMO and CRO" market report?

 Key Market Segments

  • By Product
    • Biologics
    • Biosimilars
  • By Source
    • Mammalian
    • Non-Mammalian
  • By Service Type
    • Contract Manufacturing
    • Contract Research
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Lonza
  • ProBioGen
  • JRS PHARMA
  • Rentschler Biotechnologie GmbH
  • Samsung BioLogics
  • Inno Biologics Sdn Bhd
  • TOYOBO CO., LTD.
  • BIOMEVA GmbH
  • Boehringer Ingelheim GmbH
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: BIOPHARMACEUTICAL CMO AND CRO MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Biologics

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Biosimilars

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: BIOPHARMACEUTICAL CMO AND CRO MARKET, BY SOURCE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Source

    • 5.2. Mammalian

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Non-Mammalian

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: BIOPHARMACEUTICAL CMO AND CRO MARKET, BY SERVICE TYPE

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Service Type

    • 6.2. Contract Manufacturing

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Contract Research

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

  • CHAPTER 7: BIOPHARMACEUTICAL CMO AND CRO MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Product

      • 7.2.3. Market Size and Forecast, By Source

      • 7.2.4. Market Size and Forecast, By Service Type

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Biopharmaceutical Cmo And Cro Market

        • 7.2.6.1. Market Size and Forecast, By Product
        • 7.2.6.2. Market Size and Forecast, By Source
        • 7.2.6.3. Market Size and Forecast, By Service Type

      • 7.2.7. Canada Biopharmaceutical Cmo And Cro Market

        • 7.2.7.1. Market Size and Forecast, By Product
        • 7.2.7.2. Market Size and Forecast, By Source
        • 7.2.7.3. Market Size and Forecast, By Service Type

      • 7.2.8. Mexico Biopharmaceutical Cmo And Cro Market

        • 7.2.8.1. Market Size and Forecast, By Product
        • 7.2.8.2. Market Size and Forecast, By Source
        • 7.2.8.3. Market Size and Forecast, By Service Type

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Product

      • 7.3.3. Market Size and Forecast, By Source

      • 7.3.4. Market Size and Forecast, By Service Type

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Biopharmaceutical Cmo And Cro Market

        • 7.3.6.1. Market Size and Forecast, By Product
        • 7.3.6.2. Market Size and Forecast, By Source
        • 7.3.6.3. Market Size and Forecast, By Service Type

      • 7.3.7. Germany Biopharmaceutical Cmo And Cro Market

        • 7.3.7.1. Market Size and Forecast, By Product
        • 7.3.7.2. Market Size and Forecast, By Source
        • 7.3.7.3. Market Size and Forecast, By Service Type

      • 7.3.8. Italy Biopharmaceutical Cmo And Cro Market

        • 7.3.8.1. Market Size and Forecast, By Product
        • 7.3.8.2. Market Size and Forecast, By Source
        • 7.3.8.3. Market Size and Forecast, By Service Type

      • 7.3.9. Spain Biopharmaceutical Cmo And Cro Market

        • 7.3.9.1. Market Size and Forecast, By Product
        • 7.3.9.2. Market Size and Forecast, By Source
        • 7.3.9.3. Market Size and Forecast, By Service Type

      • 7.3.10. UK Biopharmaceutical Cmo And Cro Market

        • 7.3.10.1. Market Size and Forecast, By Product
        • 7.3.10.2. Market Size and Forecast, By Source
        • 7.3.10.3. Market Size and Forecast, By Service Type

      • 7.3.11. Russia Biopharmaceutical Cmo And Cro Market

        • 7.3.11.1. Market Size and Forecast, By Product
        • 7.3.11.2. Market Size and Forecast, By Source
        • 7.3.11.3. Market Size and Forecast, By Service Type

      • 7.3.12. Rest Of Europe Biopharmaceutical Cmo And Cro Market

        • 7.3.12.1. Market Size and Forecast, By Product
        • 7.3.12.2. Market Size and Forecast, By Source
        • 7.3.12.3. Market Size and Forecast, By Service Type

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Product

      • 7.4.3. Market Size and Forecast, By Source

      • 7.4.4. Market Size and Forecast, By Service Type

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Biopharmaceutical Cmo And Cro Market

        • 7.4.6.1. Market Size and Forecast, By Product
        • 7.4.6.2. Market Size and Forecast, By Source
        • 7.4.6.3. Market Size and Forecast, By Service Type

      • 7.4.7. Japan Biopharmaceutical Cmo And Cro Market

        • 7.4.7.1. Market Size and Forecast, By Product
        • 7.4.7.2. Market Size and Forecast, By Source
        • 7.4.7.3. Market Size and Forecast, By Service Type

      • 7.4.8. India Biopharmaceutical Cmo And Cro Market

        • 7.4.8.1. Market Size and Forecast, By Product
        • 7.4.8.2. Market Size and Forecast, By Source
        • 7.4.8.3. Market Size and Forecast, By Service Type

      • 7.4.9. South Korea Biopharmaceutical Cmo And Cro Market

        • 7.4.9.1. Market Size and Forecast, By Product
        • 7.4.9.2. Market Size and Forecast, By Source
        • 7.4.9.3. Market Size and Forecast, By Service Type

      • 7.4.10. Australia Biopharmaceutical Cmo And Cro Market

        • 7.4.10.1. Market Size and Forecast, By Product
        • 7.4.10.2. Market Size and Forecast, By Source
        • 7.4.10.3. Market Size and Forecast, By Service Type

      • 7.4.11. Thailand Biopharmaceutical Cmo And Cro Market

        • 7.4.11.1. Market Size and Forecast, By Product
        • 7.4.11.2. Market Size and Forecast, By Source
        • 7.4.11.3. Market Size and Forecast, By Service Type

      • 7.4.12. Malaysia Biopharmaceutical Cmo And Cro Market

        • 7.4.12.1. Market Size and Forecast, By Product
        • 7.4.12.2. Market Size and Forecast, By Source
        • 7.4.12.3. Market Size and Forecast, By Service Type

      • 7.4.13. Indonesia Biopharmaceutical Cmo And Cro Market

        • 7.4.13.1. Market Size and Forecast, By Product
        • 7.4.13.2. Market Size and Forecast, By Source
        • 7.4.13.3. Market Size and Forecast, By Service Type

      • 7.4.14. Rest of Asia Pacific Biopharmaceutical Cmo And Cro Market

        • 7.4.14.1. Market Size and Forecast, By Product
        • 7.4.14.2. Market Size and Forecast, By Source
        • 7.4.14.3. Market Size and Forecast, By Service Type

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Product

      • 7.5.3. Market Size and Forecast, By Source

      • 7.5.4. Market Size and Forecast, By Service Type

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Biopharmaceutical Cmo And Cro Market

        • 7.5.6.1. Market Size and Forecast, By Product
        • 7.5.6.2. Market Size and Forecast, By Source
        • 7.5.6.3. Market Size and Forecast, By Service Type

      • 7.5.7. South Africa Biopharmaceutical Cmo And Cro Market

        • 7.5.7.1. Market Size and Forecast, By Product
        • 7.5.7.2. Market Size and Forecast, By Source
        • 7.5.7.3. Market Size and Forecast, By Service Type

      • 7.5.8. Saudi Arabia Biopharmaceutical Cmo And Cro Market

        • 7.5.8.1. Market Size and Forecast, By Product
        • 7.5.8.2. Market Size and Forecast, By Source
        • 7.5.8.3. Market Size and Forecast, By Service Type

      • 7.5.9. UAE Biopharmaceutical Cmo And Cro Market

        • 7.5.9.1. Market Size and Forecast, By Product
        • 7.5.9.2. Market Size and Forecast, By Source
        • 7.5.9.3. Market Size and Forecast, By Service Type

      • 7.5.10. Argentina Biopharmaceutical Cmo And Cro Market

        • 7.5.10.1. Market Size and Forecast, By Product
        • 7.5.10.2. Market Size and Forecast, By Source
        • 7.5.10.3. Market Size and Forecast, By Service Type

      • 7.5.11. Rest of LAMEA Biopharmaceutical Cmo And Cro Market

        • 7.5.11.1. Market Size and Forecast, By Product
        • 7.5.11.2. Market Size and Forecast, By Source
        • 7.5.11.3. Market Size and Forecast, By Service Type

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning, 2024

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Boehringer Ingelheim GmbH

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Lonza

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Inno Biologics Sdn Bhd

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Rentschler Biotechnologie GmbH

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. JRS PHARMA

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. BIOMEVA GmbH

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. ProBioGen

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. TOYOBO CO., LTD.

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Samsung BioLogics

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL BIOPHARMACEUTICAL CMO AND CRO MARKET, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL BIOPHARMACEUTICAL CMO AND CRO MARKET FOR BIOLOGICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL BIOPHARMACEUTICAL CMO AND CRO MARKET FOR BIOSIMILARS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL BIOPHARMACEUTICAL CMO AND CRO MARKET, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL BIOPHARMACEUTICAL CMO AND CRO MARKET FOR MAMMALIAN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL BIOPHARMACEUTICAL CMO AND CRO MARKET FOR NON-MAMMALIAN, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL BIOPHARMACEUTICAL CMO AND CRO MARKET, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL BIOPHARMACEUTICAL CMO AND CRO MARKET FOR CONTRACT MANUFACTURING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL BIOPHARMACEUTICAL CMO AND CRO MARKET FOR CONTRACT RESEARCH, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL BIOPHARMACEUTICAL CMO AND CRO MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. NORTH AMERICA BIOPHARMACEUTICAL CMO AND CRO, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. NORTH AMERICA BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 13. NORTH AMERICA BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 14. NORTH AMERICA BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 15. U.S. BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 16. U.S. BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 17. U.S. BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 18. CANADA BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 19. CANADA BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 20. CANADA BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 21. MEXICO BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 22. MEXICO BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 23. MEXICO BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 24. EUROPE BIOPHARMACEUTICAL CMO AND CRO, BY REGION, 2025-2033 ($MILLION)
  • TABLE 25. EUROPE BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 26. EUROPE BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 27. EUROPE BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 28. FRANCE BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 29. FRANCE BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 30. FRANCE BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 31. GERMANY BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 32. GERMANY BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 33. GERMANY BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 34. ITALY BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 35. ITALY BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 36. ITALY BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 37. SPAIN BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 38. SPAIN BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 39. SPAIN BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 40. UK BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 41. UK BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 42. UK BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 43. RUSSIA BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 44. RUSSIA BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 45. RUSSIA BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 46. REST OF EUROPE BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 47. REST OF EUROPE BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 48. REST OF EUROPE BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 49. ASIA-PACIFIC BIOPHARMACEUTICAL CMO AND CRO, BY REGION, 2025-2033 ($MILLION)
  • TABLE 50. ASIA-PACIFIC BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 51. ASIA-PACIFIC BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 52. ASIA-PACIFIC BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 53. CHINA BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 54. CHINA BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 55. CHINA BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 56. JAPAN BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 57. JAPAN BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 58. JAPAN BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 59. INDIA BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 60. INDIA BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 61. INDIA BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 62. SOUTH KOREA BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 63. SOUTH KOREA BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 64. SOUTH KOREA BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 65. AUSTRALIA BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 66. AUSTRALIA BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 67. AUSTRALIA BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 68. THAILAND BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 69. THAILAND BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 70. THAILAND BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 71. MALAYSIA BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 72. MALAYSIA BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 73. MALAYSIA BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 74. INDONESIA BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 75. INDONESIA BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 76. INDONESIA BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 77. REST OF ASIA PACIFIC BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 78. REST OF ASIA PACIFIC BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 79. REST OF ASIA PACIFIC BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 80. LAMEA BIOPHARMACEUTICAL CMO AND CRO, BY REGION, 2025-2033 ($MILLION)
  • TABLE 81. LAMEA BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 82. LAMEA BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 83. LAMEA BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 84. BRAZIL BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 85. BRAZIL BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 86. BRAZIL BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 87. SOUTH AFRICA BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 88. SOUTH AFRICA BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 89. SOUTH AFRICA BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 90. SAUDI ARABIA BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 91. SAUDI ARABIA BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 92. SAUDI ARABIA BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 93. UAE BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 94. UAE BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 95. UAE BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 96. ARGENTINA BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 97. ARGENTINA BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 98. ARGENTINA BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 99. REST OF LAMEA BIOPHARMACEUTICAL CMO AND CRO, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 100. REST OF LAMEA BIOPHARMACEUTICAL CMO AND CRO, BY SOURCE, 2025-2033 ($MILLION)
  • TABLE 101. REST OF LAMEA BIOPHARMACEUTICAL CMO AND CRO, BY SERVICE TYPE, 2025-2033 ($MILLION)
  • TABLE 102. BOEHRINGER INGELHEIM GMBH: KEY EXECUTIVES
  • TABLE 103. BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT
  • TABLE 104. BOEHRINGER INGELHEIM GMBH: OPERATING SEGMENTS
  • TABLE 105. BOEHRINGER INGELHEIM GMBH: PRODUCT PORTFOLIO
  • TABLE 106. BOEHRINGER INGELHEIM GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 107. LONZA: KEY EXECUTIVES
  • TABLE 108. LONZA: COMPANY SNAPSHOT
  • TABLE 109. LONZA: OPERATING SEGMENTS
  • TABLE 110. LONZA: PRODUCT PORTFOLIO
  • TABLE 111. LONZA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112. INNO BIOLOGICS SDN BHD: KEY EXECUTIVES
  • TABLE 113. INNO BIOLOGICS SDN BHD: COMPANY SNAPSHOT
  • TABLE 114. INNO BIOLOGICS SDN BHD: OPERATING SEGMENTS
  • TABLE 115. INNO BIOLOGICS SDN BHD: PRODUCT PORTFOLIO
  • TABLE 116. INNO BIOLOGICS SDN BHD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. RENTSCHLER BIOTECHNOLOGIE GMBH: KEY EXECUTIVES
  • TABLE 118. RENTSCHLER BIOTECHNOLOGIE GMBH: COMPANY SNAPSHOT
  • TABLE 119. RENTSCHLER BIOTECHNOLOGIE GMBH: OPERATING SEGMENTS
  • TABLE 120. RENTSCHLER BIOTECHNOLOGIE GMBH: PRODUCT PORTFOLIO
  • TABLE 121. RENTSCHLER BIOTECHNOLOGIE GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 122. JRS PHARMA: KEY EXECUTIVES
  • TABLE 123. JRS PHARMA: COMPANY SNAPSHOT
  • TABLE 124. JRS PHARMA: OPERATING SEGMENTS
  • TABLE 125. JRS PHARMA: PRODUCT PORTFOLIO
  • TABLE 126. JRS PHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 127. BIOMEVA GMBH: KEY EXECUTIVES
  • TABLE 128. BIOMEVA GMBH: COMPANY SNAPSHOT
  • TABLE 129. BIOMEVA GMBH: OPERATING SEGMENTS
  • TABLE 130. BIOMEVA GMBH: PRODUCT PORTFOLIO
  • TABLE 131. BIOMEVA GMBH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 132. PROBIOGEN: KEY EXECUTIVES
  • TABLE 133. PROBIOGEN: COMPANY SNAPSHOT
  • TABLE 134. PROBIOGEN: OPERATING SEGMENTS
  • TABLE 135. PROBIOGEN: PRODUCT PORTFOLIO
  • TABLE 136. PROBIOGEN: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 137. FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC.: KEY EXECUTIVES
  • TABLE 138. FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC.: COMPANY SNAPSHOT
  • TABLE 139. FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC.: OPERATING SEGMENTS
  • TABLE 140. FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC.: PRODUCT PORTFOLIO
  • TABLE 141. FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 142. TOYOBO CO., LTD.: KEY EXECUTIVES
  • TABLE 143. TOYOBO CO., LTD.: COMPANY SNAPSHOT
  • TABLE 144. TOYOBO CO., LTD.: OPERATING SEGMENTS
  • TABLE 145. TOYOBO CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 146. TOYOBO CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 147. SAMSUNG BIOLOGICS: KEY EXECUTIVES
  • TABLE 148. SAMSUNG BIOLOGICS: COMPANY SNAPSHOT
  • TABLE 149. SAMSUNG BIOLOGICS: OPERATING SEGMENTS
  • TABLE 150. SAMSUNG BIOLOGICS: PRODUCT PORTFOLIO
  • TABLE 151. SAMSUNG BIOLOGICS: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOPHARMACEUTICAL CMO AND CRO MARKET SEGMENTATION
  • FIGURE 2. GLOBAL BIOPHARMACEUTICAL CMO AND CRO MARKET
  • FIGURE 3. SEGMENTATION BIOPHARMACEUTICAL CMO AND CRO MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN BIOPHARMACEUTICAL CMO AND CRO MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALBIOPHARMACEUTICAL CMO AND CRO MARKET
  • FIGURE 11. BIOPHARMACEUTICAL CMO AND CRO MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. BIOPHARMACEUTICAL CMO AND CRO MARKET FOR BIOLOGICS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. BIOPHARMACEUTICAL CMO AND CRO MARKET FOR BIOSIMILARS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. BIOPHARMACEUTICAL CMO AND CRO MARKET SEGMENTATION, BY BY SOURCE
  • FIGURE 15. BIOPHARMACEUTICAL CMO AND CRO MARKET FOR MAMMALIAN, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. BIOPHARMACEUTICAL CMO AND CRO MARKET FOR NON-MAMMALIAN, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. BIOPHARMACEUTICAL CMO AND CRO MARKET SEGMENTATION, BY BY SERVICE TYPE
  • FIGURE 18. BIOPHARMACEUTICAL CMO AND CRO MARKET FOR CONTRACT MANUFACTURING, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. BIOPHARMACEUTICAL CMO AND CRO MARKET FOR CONTRACT RESEARCH, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 21. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 22. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 23. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 24. COMPETITIVE DASHBOARD
  • FIGURE 25. COMPETITIVE HEATMAP: BIOPHARMACEUTICAL CMO AND CRO MARKET
  • FIGURE 26. TOP PLAYER POSITIONING, 2024
  • FIGURE 27. BOEHRINGER INGELHEIM GMBH: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 28. BOEHRINGER INGELHEIM GMBH: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 29. BOEHRINGER INGELHEIM GMBH: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 30. LONZA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 31. LONZA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 32. LONZA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 33. INNO BIOLOGICS SDN BHD: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 34. INNO BIOLOGICS SDN BHD: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 35. INNO BIOLOGICS SDN BHD: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 36. RENTSCHLER BIOTECHNOLOGIE GMBH: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 37. RENTSCHLER BIOTECHNOLOGIE GMBH: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 38. RENTSCHLER BIOTECHNOLOGIE GMBH: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 39. JRS PHARMA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. JRS PHARMA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. JRS PHARMA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. BIOMEVA GMBH: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. BIOMEVA GMBH: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. BIOMEVA GMBH: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. PROBIOGEN: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. PROBIOGEN: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. PROBIOGEN: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. FUJIFILM DIOSYNTH BIOTECHNOLOGIES U.S.A., INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. TOYOBO CO., LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. TOYOBO CO., LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. TOYOBO CO., LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 54. SAMSUNG BIOLOGICS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 55. SAMSUNG BIOLOGICS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 56. SAMSUNG BIOLOGICS: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Biopharmaceutical CMO and CRO Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved